CONMED Long-Term Investments 2010-2024 | CNMD

CONMED long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
CONMED Annual Long-Term Investments
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
CONMED Quarterly Long-Term Investments
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $2.215B $1.245B
CONMED Corporation is a major medical products manufacturer specializing in surgical instruments and devices for minimally invasive procedures and monitoring. A significant portion of the company's revenues are derived from products designed for the orthopedic surgery markets of arthroscopy and powered surgical instruments. The company also sells products for general and other surgical specialties such as electrosurgery systems for all types of surgery, and endosurgery instruments for minimally invasive laparoscopic surgery. Patient Care products, including ECG electrodes for heart monitoring and pulse oximetry for blood oxygenation monitoring, are provided for various clinical settings.The company operates in two revenue segments: Orthopedic Surgery and General Surgery.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $79.753B 21.76
Becton Dickinson (BDX) United States $65.165B 17.13
Cardinal Health (CAH) United States $29.869B 16.20
West Pharmaceutical Services (WST) United States $23.239B 47.47
Labcorp (LH) United States $20.088B 16.66
Cooper (COO) United States $19.898B 28.32
Align Technology (ALGN) United States $17.037B 32.60
Henry Schein (HSIC) United States $9.198B 17.52
Merit Medical Systems (MMSI) United States $6.121B 31.26
DENTSPLY SIRONA (XRAY) United States $3.705B 10.08
Patterson (PDCO) United States $1.788B 9.43
STAAR Surgical (STAA) United States $1.312B 48.42
Lifevantage (LFVN) United States $0.165B 21.93
Pro-Dex (PDEX) United States $0.138B 27.49